Journal
HIV CLINICAL TRIALS
Volume 11, Issue 3, Pages 127-132Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1310/hct1103-125
Keywords
efavirenz; HIV-1; maraviroc; treatment naive; virologic response
Categories
Funding
- Pfizer Global Research and Development
- Pfizer, Inc.
- ViiV Healthcare
- Merck Sharp Dohme
- Tibotec
- Stendhal
- Abbott
- Gilead
- BMS
- GlaxoSmithKline
- Ardea Biosciences Avexa
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Pain Therapeutics
- Progenics
- Tobira Therapeutics
- Virxsys
Ask authors/readers for more resources
Background: The MERIT study evaluated maraviroc versus efavirenz, both with zidovudine/lamivudine, in treatment-naive patients with CCR5-tropic (R5) HIV-1. Post hoc analyses previously assessed week 48 outcomes in patients rescreened with R5 virus by a more sensitive tropism assay. Methods: Week 96 efficacy (post hoc, n = 614) and safety (n = 721) were assessed. Results: Proportions of subjects <50 copies/mL (58.8% maraviroc, 62.7% efavirenz) and time to loss of virologic response (TLOVR) responders (<50 copies/mL: 60.5% vs 60.7%) were similar. Maraviroc recipients had greater CD4 increases (+212 vs+ 171 cells/mm(3)) and fewer adverse event discontinuations (6.1% vs 15.5%), malignancies, and category C events. Conclusion: Week 96 data confirm week 48 observations in MERIT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available